Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Total Liabilities (2022 - 2025)

Historic Total Liabilities for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $146.7 million.

  • Centessa Pharmaceuticals' Total Liabilities rose 3269.0% to $146.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.7 million, marking a year-over-year increase of 3269.0%. This contributed to the annual value of $175.3 million for FY2024, which is 4133.08% up from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' Total Liabilities is $146.7 million, which was up 3269.0% from $147.2 million recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' Total Liabilities peaked at $175.3 million during Q4 2024, and registered a low of $101.0 million during Q2 2022.
  • Moreover, its 4-year median value for Total Liabilities was $113.0 million (2024), whereas its average is $122.2 million.
  • Data for Centessa Pharmaceuticals' Total Liabilities shows a peak YoY increase of 4133.08% (in 2024) and a maximum YoY decrease of 626.92% (in 2024) over the last 5 years.
  • Over the past 4 years, Centessa Pharmaceuticals' Total Liabilities (Quarter) stood at $108.1 million in 2022, then grew by 14.67% to $124.0 million in 2023, then skyrocketed by 41.33% to $175.3 million in 2024, then dropped by 16.28% to $146.7 million in 2025.
  • Its last three reported values are $146.7 million in Q3 2025, $147.2 million for Q2 2025, and $141.6 million during Q1 2025.